Girard Partners LTD. cut its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 8.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 32,563 shares of the biopharmaceutical company’s stock after selling 3,010 shares during the quarter. Girard Partners LTD.’s holdings in Bristol-Myers Squibb were worth $1,814,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of BMY. Tradewinds Capital Management LLC increased its position in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the period. Blue Chip Partners Inc. increased its position in shares of Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 17 shares during the period. Proficio Capital Partners LLC grew its holdings in shares of Bristol-Myers Squibb by 29.6% in the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 504 shares during the last quarter. American National Bank grew its holdings in shares of Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares during the last quarter. Finally, Heritage Trust Co acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter worth $123,000. Institutional investors own 69.51% of the company’s stock.

Bristol-Myers Squibb Company (NYSE BMY) opened at $60.99 on Tuesday. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market capitalization of $99,609.57, a PE ratio of 20.56, a P/E/G ratio of 2.40 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.77 earnings per share. equities analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 61.42%.

A number of equities analysts recently issued reports on the company. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 target price on the stock. in a report on Tuesday, August 22nd. Citigroup Inc. set a $72.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Deutsche Bank AG set a $55.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, July 17th. Finally, Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Wednesday, August 16th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $64.93.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Shares Sold by Girard Partners LTD.” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/14/bristol-myers-squibb-company-bmy-shares-sold-by-girard-partners-ltd.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.